Life Extension Magazine®

Issue: Jun 2013

Dangerous Misconceptions

Heart disease kills more women than men, yet most females remain unaware of blood markers that assess their risk of cancer and vascular disease. Maturing women require proper blood tests to identify these reversible risk factors before heart attack, stroke, or malignancy strikes. Find out about other fallacies that result in millions of needless deaths each year.

By William Faloon.

William Faloon
William Faloon

I’ll never forget a call I received from the coroner’s office in 1981 questioning how a 17-year-old boy could have died of colon cancer. The county Medical Examiner stated to me that this was “impossible.

I told the Medical Examiner that while I had never heard of anyone this young dying of colon cancer, this is what the records reflected. The Medical Examiner insisted on talking to the treating physician. A few hours later, the Medical Examiner called me back apologizing for his error.

Recent studies now show increasing rates of colon cancer in young adults—higher than anyone had ever expected.1-4 The reason so many of these young people die is their doctors do not consider colon cancer as a cause of their symptoms and thus fail to initiate timely diagnosis and treatment.1,3

Move forward to year 2013, and physicians continue to wallow in a sea of unawareness when it comes to understanding common diseases. The tragic result is failure to implement changes that would prevent adverse outcomes for millions of Americans every year.

One critical mission of Life Extension® is to break down barriers of medical ignorance that cause humans to senselessly suffer and die.

Heart Attacks Kill More Women than Men

Heart Attacks Kill More Women than Men  

Heart disease is often thought of as a problem that primarily affects men. The reality since 1984 is that more women die from heart disease than men.5

According to a prominent Los Angeles heart surgeon, the most common way a woman presents with heart disease is dead on arrival at the hospital.

Women often downplay their symptoms and wait longer before going to the emergency room. Women also present with different symptoms than men, causing doctors to overlook many cases of heart disease.

Women historically receive less aggressive heart disease prevention and treatment. As a result, when women are finally diagnosed, they usually have more advanced heart disease and their prognosis is poorer.

Startling Statistics

Right now, more than 1 in 3 female adults in the United States has some form of cardiovascular disease.6

Cardiovascular disease of all forms killed 419,730 women in 2008, while all forms of cancer combined caused 270,210 female deaths that year.6

While women justifiably fear breast cancer (in recent years, it has killed more than 40,000 females a year), cardiovascular disease claims the lives of more than ten times more women.6

Women over age 40 are diligently having mammograms in an attempt to detect breast cancer at an early curable stage. Most are overlooking important blood tests that can be used to slash far more prevalent cardiovascular risk factors.

Not only do blood test results enable women to prevent heart attack and stroke, they also reveal correctable factors that can reduce cancer risk.

Mammograms only detect the presence of lesions that may be malignant. Comprehensive blood tests, on the other hand, enable women to protect themselves against virtually every disease associated with aging...including breast cancer in some instances!

Blood Markers of Impending Heart Attack and Stroke

cardiovascular system  

Almost half of all American women have blood cholesterol levels over 200 mg/dL,7 yet only the minority knows this.

Similar to men, women with elevated LDL,8-10 glucose,11-14 triglycerides,15-18and C-reactive protein,19-22 (and low HDL)23-27 have sharply higher vascular disease risks. Some studies show that high glucose and triglyceride blood levels in women create a greater vascular impact than in men.25,28-31

Heart disease accounts for more than a third of all female deaths in the United States,7 yet the vast majority do not know what their cardiovascular disease blood markers are. The consequence of this misconception is that heart failure and stroke are leading causes of disability and death of American women.

Females over age 35-40 should have comprehensive blood tests annually to identify proven heart attack/stroke risk factors and take corrective actions when any marker is out of optimal range.

DHEA Blood Levels and Coronary Deaths

A number of studies associate low DHEA blood levels with higher rates of endothelial dysfunction and heart attack.33-35

In 2010, a study showed that women with the lowest DHEA more than doubled their rate of dying from coronary artery disease compared to women with higher DHEA blood levels.36

This six-year study showed more than twice as many women with low DHEA died from all-causes compared to women with higher DHEA blood readings.

The take-home lesson from this and similar studies is for aging humans to know their DHEA blood levels and take the appropriate DHEA dose to achieve youthful levels shown to protect against mortality.

Polycystic Ovary Syndrome…An Underdiagnosed Problem

Some women suffer excess accumulation of body fat caused not by overeating, but from a disorder called polycystic ovary syndrome that is characterized by out-of-balance hormones.37,38

The drug that can be highly effective in treating this hormone imbalance is metformin. It reduces excess insulin39-43 and testosterone levels,39,40,44 while helping women shed fat pounds.39,45

In one study, 22 morbidly obese women with polycystic ovary syndrome were treated with metformin. After 24 weeks, they lost an average of 6% of their body weight (18 pounds). In the same study, women who continued on metformin after one year maintained their weight loss while those who stopped regained 50% of their weight.46

Those suffering from polycystic ovary syndrome have higher rates of diabetes,47-52 coronary blockage,47,52-56 and metabolic syndrome.47,54,57-59

For women suffering from frank polycystic ovary syndrome, or just too much insulin-testosterone, low-cost blood tests can identify the underlying problem and enable a physician to properly prescribe metformin and other therapies to safely induce weight loss and reduce cardiovascular risks.

Heart Attack Symptoms in Women

The most common heart attack symptom in women is pain, pressure, or discomfort in the chest. But in women, it’s not always severe or the most prominent symptom. Over 40% of women suffering a heart attack may not even experience chest pains (angina).32 Women are more likely than men to have heart attack symptoms unrelated to chest pain, such as the following:28

  • Neck, shoulder, upper back, or abdominal discomfort
  • Shortness of breath
  • Nausea or vomiting
  • Sweating
  • Lightheadedness or dizziness
  • Unusual fatigue

Men are more likely to experience classic signs/symptoms of coronary heart disease like crushing left-sided chest pain that radiates to the left arm or jaw. Women, on the other hand, are more likely to report shortness of breath, weakness or fatigue, dizziness, and palpitations.

This may be because women tend to have blockages not only in their main arteries, but also in the smaller arteries that supply blood to the heart—a condition called small vessel heart disease or microvascular disease.28

Many women tend to show up in emergency rooms after much heart damage has already occurred because their symptoms are not those typically associated with a heart attack.

Blood Glucose and Cancer Risk

Those with higher glucose and insulin suffer greater rates of all cancers.60,61

Gestational diabetes is a temporary state of glucose intolerance associated with pregnancy. Its long- term effect in women, however, is a 7-fold increase in pancreatic cancer.62

A 13.5-year study showed that women in the highest glucose quartile were 63% more likely to develop breast cancer.63 Another study that included 33,293 women measured fasting and post-load glucose and found those in the highest ranges were 75% more likely to develop cancer.64

Diabetics have higher cancer risks. One analysis of diabetic women showed a 22% increased breast cancer risk, but even those with impaired glucose metabolism develop breast cancer with greater frequency.65 The researcher who conducted this study concluded that increased cancer risk occurred even when glucose levels were “below the diagnostic threshold for diabetes.

Keeping glucose in the low ranges protects against cardiovascular disease, helps shed fat pounds, and reduces cancer risk.

Cancer Patients Especially Vulnerable to High Glucose

The impact of elevated blood glucose on cancer patients is devastating.

The body responds to higher glucose levels by secreting more insulin (which promotes tumor growth). A study of 1,695 non-diabetic men and women found that, of the participants that developed cancer, there was a 37% increase in all-cause mortality for those in the highest quartile of fasting insulin.75

A study of newly diagnosed non-small cell lung cancer patients showed a 69% increased risk of all-cause mortality when fasting glucose was over 126 mg/dL.76

An interesting analysis was done on diabetic and non-diabetic breast cancer patients. There was no difference in overall survival between the two groups, but elevated glucose in either group was associated with poorer outcomes and an elevated risk of death.77 This study supports previous findings that high blood glucose is associated with poor response to breast cancer treatment.78-84

In a decade-long study of 3,003 breast cancer survivors, risk of all-cause mortality was twice as high in women with a hemoglobin A1c reading greater than 7% compared to women with less than 6.5%.79 Hemoglobin A1c is a blood test that measures average glucose levels over the previous approximately three months.

These findings together support the role of a healthy diet and lifestyle in the overall treatment of cancer.

Since people often make too much glucose in their liver (gluconeogenesis), even those who avoid glucose-spiking carbohydrates and starches need to take additional steps to keep their glucose/insulin levels low. The drug metformin85,86 and nutritional supplement green coffee bean extract87,88 inhibit glucose production in the liver, thus lowering blood glucose to safer ranges.

Cancer patients should insist on regular blood tests to check their fasting glucose, fasting insulin, and after-meal glucose.

Lung Cancer Kills Many Non-Smokers

Lung cancer kills so many cigarette smokers that many people mistakenly believe that non-smokers don’t develop it. The facts are that lung cancer kills around 24,000 non-smokers each year in the United States, making it among the top 10 most lethal cancers in the US.66 Additionally, lung cancer in people who’ve never smoked is on the rise. In the US, 17.5% of lung cancers occur in this group, and among women the figure is even higher. In some areas of the world, such as Southeast Asia, as many as 50% of female lung cancer cases are found in women that have never smoked.67

What is particularly regrettable is that many of these non-smokers are victimized by second-hand smoke, a carcinogen that I was forcibly exposed to in my early life.

The carnage caused by second-hand smoke, which adds up to millions of disabled and dead innocent Americans, is one of the great medical travesties of the past 100 years.68-71 The dangers of second-hand smoke are still not fully appreciated, as millions of children are exposed each year in the home environment while society prioritizes far less important issues.

Scientific research has shown that a blood marker of cardiovascular risk (C-reactive protein) is also elevated in lung and colon cancer patients.72-74 What is encouraging about this is that the steps people take to reduce vascular disease (such as lowering C-reactive protein) might help protect against common malignancies.

C-Reactive Protein: A New Cancer Blood Marker?

C-Reactive Protein: A New Cancer Blood Marker?  

Inflammation is an underlying cause of virtually all degenerative disorders, including vascular disease, cancer, and dementia.89-97 The C-reactive protein (CRP) blood test is a general measurement of inflammation in the body.

In a general population study, individuals with the highest CRP levels had a 1.3-fold increased risk of cancer of any type, and a 2-fold increased risk of lung cancer. Among individuals diagnosed with cancer during the study period, individuals with a high baseline CRP (over 3mg/L) had an 80% greater risk of early death compared to those with low CRP levels (<1mg/L).98

This corroborates numerous other studies showing greater cancer risk, incidence, and mortality in those with elevated CRP blood test readings.99-108

A study was done with cancer survivors to measure fatigue and other common side effects of conventional therapy. Survivors with high CRP had 1.8 times greater odds of fatigue after adjusting for all other factors. This study showed that higher ingestion of omega-6 fats relative to omega-3 fats was associated with higher C-reactive protein levels.109

A wealth of data shows that a high-sensitivity CRP blood test may become a new marker in identifying those at greater risk for developing cancer and dying from it.110-112 Ideal CRP levels in women are less than 1.0 mg/L.113 If your blood test result shows CRP readings over 1.5 mg/L, there are a number of proven ways to lower it to safer ranges.

While CRP testing is done today primarily to identify those at higher risk for stroke, heart attack, diabetes,and dementia, it may also turn out to be a useful tool in the prevention and treatment of common cancers.

Don’t Be a Victim of Deadly Misconceptions

The incidence of type II diabetes and related disorders such as obesity, vascular disease, and cancer is skyrocketing, yet comprehensive blood testing can identify underlying factors that if corrected in time, can prevent an epidemic of tragic outcomes.

Most of you reading this have been victimized by second-hand cigarette smoke, yet controlling your C-reactive protein and glucose blood levels may lower your risk of lung cancer.

So many female Life Extension members have been helped when their hormone levels are checked and balanced. Not only do they feel better when all their blood markers are restored to youthful ranges, but their risk of degenerative disease is substantively reduced.

The high cost and inconvenience of today’s broken sick-care system prevents most healthy people from having their blood thoroughly analyzed. Life Extension broke down these barriers 17 years ago by offering a broad range of blood tests for far less than what commercial labs charge.

Instead of having to make a doctor’s appointment, most of our members walk in at their convenience to a blood drawing station in their neighborhood.

Once-A-Year Blood Test Super Sale

The comprehensive Female or Male Blood Test Panels contain more specialized blood measurements than virtually any standard battery of tests. Commercial labs often charge a king’s ransom to perform ALL of these tests.

Yet, Life Extension members can order the Female or Male Blood Test Panel for only $269.

This year we were able to add the hemoglobin A1c test to the Male and Female Panels at no extra charge. The next page describes the many tests included in the comprehensive Male or Female Panels. At the discounted price of $269, these blood tests are the best investment you may ever make in your health and longevity.

If you’re reading this and are not already a Life Extension member, please join today. The huge savings on the Female and/or Male Panel more than covers the $75 membership fee.

To order your blood tests and/or join the Foundation, call 1-800-841-5433 (24 hours).

For longer life,

For Longer Life

William Faloon

Male and Female Blood Test Panels

Unlike commercial blood tests that evaluate only a few disease risk factors, Life Extension’s Male and Female Blood Test. Panels measure a wide range of blood markers that predispose people to common age-related disorders. This year we are able to add the hemoglobin A1c test to the Male and Female Panels at no additional cost. Hemoglobin A1c is a measurement of long-term glucose control. Just look at the huge number of parameters included in the Male and Female Blood Test Panels:


Lipid Profile

Total Cholesterol
LDL (low-density lipoprotein)
HDL (high-density lipoprotein)

Cardiac Markers

C-Reactive Protein (high sensitivity)


Free and Total Testosterone
Estradiol (an estrogen)
TSH (thyroid function)
Vitamin D (25-hydroxyvitamin D)

Metabolic Profile

Kidney function tests: creatinine, BUN, uric acid, BUN/creatinine ratio
Liver function tests: AST, ALT, LDH, GGT, bilirubin, alkaline phosphatase
Blood minerals: calcium, potassium, phosphorus, sodium, chloride, iron
Blood proteins: albumin, globulin, total protein, albumin/globulin ratio
Hemoglobin A1c (Now Includes HEMOGLOBIN A1c)

Complete Blood Count (CBC)

Red Blood Cell count including: hemoglobin, hematocrit, MCV, MCH, MCHC, RDW
White Blood Cell count including: lymphocytes, monocytes, eosinophils, neutrophils, basophils
Platelet count

Cancer Marker

PSA (Prostate Specific Antigen)

Lipid Profile

Total Cholesterol
LDL (low-density lipoprotein)
HDL (high-density lipoprotein)

Cardiac Markers

C-Reactive Protein (high sensitivity)


Free and Total Testosterone
Estradiol (an estrogen)
TSH (thyroid function)
Vitamin D (25-hydroxyvitamin D)

Metabolic Profile

Kidney function tests: creatinine, BUN, uric acid, BUN/creatinine ratio
Liver function tests: AST, ALT, LDH, GGT, bilirubin, alkaline phosphatase
Blood minerals: calcium, potassium, phosphorus, sodium, chloride, iron
Blood proteins: albumin, globulin, total protein, albumin/globulin ratio
Hemoglobin A1c (Now Includes HEMOGLOBIN A1c)

Complete Blood Count (CBC)

Red Blood Cell count including: hemoglobin, hematocrit, MCV, MCH, MCHC, RDW
White Blood Cell count including:
lymphocytes, monocytes, eosinophils, neutrophils, basophils
Platelet count

Non-member retail price: $400 • Special Member Discount Price: $199. Blood Test Super Sale — April 1 through June 3, 2013.
To obtain these comprehensive Male or Female Panels at these low prices, call 1-800-208-3444 to order your requisition forms.
Then—at your convenience—you can visit one of the blood-drawing facilities provided by LabCorp in your area.
(Restrictions apply in NY, NJ, RI, MA, MD)


  1. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1695-8.
  2. Tohmé C, Labaki M, Hajj G, Abboud B, Noun R, Sarkis R. Colorectal cancer in young patients: presentation, clinicopathological characteristics and outcome. J Med Liban. 2008 Oct-Dec;56(4):208-14.
  3. O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003 Oct;69(10):866-72.
  4. Mitry E, Benhamiche AM, Jouve JL, Clinard F, Finn-Faivre C, Faivre J. Colorectal adenocarcinoma in patients under 45 years of age: comparison with older patients in a well-defined French population. Dis Colon Rectum. 2001 Mar;44(3):380-7.
  5. Available at: Accessed February 4, 2013.
  6. Available at: Accessed February 4, 2013.
  7. Available at: Accessed February 4, 2013.
  8. Montalcini T, Gorgone G, Federico D, et al. Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2005 Oct;15(5):368-72.
  9. LaRosa JC. Women, lipoproteins and cardiovascular disease risk. Can J Cardiol. 1990 May;6 Suppl B:23B-9B.
  10. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992 Jan-Mar;2(1-2):161-76.
  11. Kim HK, Kim CH, Kim EH, et al. Impaired fasting glucose and risk of cardiovascular disease in korean men and women: the korean heart study. Diabetes Care. 2013 Feb;36(2):328-35.
  12. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010 Mar 30;55(13):1310-7.
  13. Liu S, Willett WC, Stampfer MJ, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 2000 Jun;71(6):1455-61.
  14. Levitzky YS, Pencina MJ, D’Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol. 2008 Jan 22;51(3):264-70.
  15. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18;298(3):309-16.
  16. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 Jul 18;298(3):299-308.
  17. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 Apr;3(2):213-9.
  18. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993 Nov 20;307(6915):1318-22.
  19. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C- reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998 Aug 25;98(8):731-3.
  20. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12): 836-43.
  21. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1668-73.
  22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65.
  23. Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Curr Opin Cardiol. 2003 Jul;18(4):286-94.
  24. Stensvold I, Urdal P, Thürmer H, Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, cardiovascular and all-cause mortality among middle-aged Norwegian men and women. Eur Heart J. 1992 Sep;13(9):1155-63.
  25. Mazza A, Tikhonoff V, Schiavon L, Casiglia E. Triglycerides +high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly. Intern Med J. 2005 Oct;35(10): 604-10.
  26. Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL. Metabolic syndrome and vascular risk: a 9-year follow-up among the aged in Finland. Acta Diabetol. 2011 Jun;48(2):157-65.
  27. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989 Jan;79(1):8-15.
  28. Available at: Accessed January 2013.
  29. Tankó LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005 Apr 19;111(15):1883-90.
  30. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and javascript:void(0)insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003 Jan 28;107(3):448-54.
  31. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006 Mar;91(3):813-9.
  32. McSweeney JC, Cody M, O’Sullivan P, Elberson K, Moser DK, Garvin BJ. Women’s early warning symptoms of acute myocardial infarction. Circulation. 2003 Nov 25;108(21):2619-23.
  33. Akishita M, Hashimoto M, Ohike Y, et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res. 2008 Jan;31(1):69-74.
  34. Sablik Z, Samborska-Sablik A, Goch JH. Concentrations of adrenal steroids and sex hormones in postmenopausal women suffering from coronary artery disease. Pol Merkur Lekarski. 2008 Oct;25(148):326-9.
  35. Słowińska-Srzednicka J, Malczewska B, Srzednicki M, et al. Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease. J Intern Med. 1995 May;237(5):465-72.
  36. Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010 Nov;95(11):4985-92.
  37. Godoy-Matos AF, Vaisman F, Pedrosa AP, Farias ML, Mendonça LM, Pinheiro MF. Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Gynecol Endocrinol. 2009 Dec;25(12):793-8.
  38. Available at: Accessed March 5, 2013.
  39. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod. 2004 Mar;19(3):510-21.
  40. Campagnoli C, Pasanisi P, Abbà C, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer. 2012 Jun;12(3):175-82.
  41. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008 Dec;8(6):501-5.
  42. Sir T, Castillo T, Munoz S, Lopez G, Calvillan M. Effects of metformin on insulin resistance in obese and hyperandrogenic women. Rev Med Chil. 1997 Dec;125(12):1457-63.
  43. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993;16(4):621-29.
  44. Velazquez EM, Mendosa S, Hamer T, Sosa F, Glucck CJ. Metformin therapy in women with polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating menstrual regularity and pregnancy. Metabolism. 1994 May;43(5):647-54.
  45. Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH. The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet. 2011 Jul;28(7):591-6.
  46. Available at: Accessed March 5, 2013.
  47. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008 Apr;93(4):1276-84.
  48. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010 Jul-Aug;16(4):347-63.
  49. Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004 Feb;56(1):41-51.
  50. Carmina E. PCOS: metabolic impact and long-term management. Minerva Ginecol. 2012 Dec;64(6):501-6.
  51. Teede HJ, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine. 2006 Aug;30(1):45-53.
  52. Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod. 2000 Apr;15(4):785-9.
  53. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Jun;88(6):2562-8.
  54. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Nov;89(11):5454-61.
  55. Glueck CJ, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism. 2009 May;58(5):714-21.
  56. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992 Aug;37(2):119-25.
  57. Vaggopoulos V, Trakakis E, Chrelias C, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with Insulin Resistance. J Endocrinol Invest. 2012 Nov 27.
  58. Huang G, Coviello A. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 2012 Dec;19(6):512-9.
  59. Pedroso DC, Melo AS, Carolo AL, Vieira CS, Rosa e Silva AC, dos Reis RM. Frequency and risk factors for metabolic syndrome in adolescents and adults women with polycystic ovary syndrome. Rev Bras Ginecol Obstet. 2012 Aug;34(8):357-61.
  60. Chen W, Lu F, Liu SJ, et al. Cancer risk and key components of metabolic syndrome: a population-based prospective cohort study in Chinese. Chin Med J (Engl). 2012 Feb;125(3):481-5.
  61. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012 2012:413782.
  62. Sella T, Chodick G, Barchana M, et al. Gestational diabetes and risk of incident primary cancer: a large historical cohort study in Israel. Cancer Causes Control. 2011 Nov;22(11):1513-20.
  63. Sieri S, Muti P, Claudia A, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2012 Feb 15;130(4):921-9.
  64. Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007 Mar;30(3):561-7.
  65. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control. 2011 Aug;22(8):1163-71.
  66. Available at: Accessed March 6, 2013.
  67. Available at: Accessed March 6, 2013
  68. Available at: Accessed February 4, 2013.
  69. Available at: Accessed February 4, 2013.
  70. Available at: Accessed February 4, 2013.
  71. Brennan P, Buffler PA, Reynolds P, et al. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer. 2004 Mar;109(1):125-31.
  72. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008 Sep 1;123(5):1133-40.
  73. Zhou B, Liu J, Wang ZM, Xi T. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One. 2012;7(8):e43075.
  74. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011 Jul 20;103(14):1112-22.
  75. Dankner R, Shanik MH, Keinan-Boker L, Cohen C, Chetrit A. Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study. Diabetes Care. 2012 Jul;35(7):1538-43.
  76. Luo J, Chen YJ, Chang LJ. Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2012 May;76(2):242-7.
  77. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, et al. Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res. 2012 2012:732027.
  78. Stebbing J, Sharma A, North B, et al. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol. 2012 Apr;23(4):860-6.
  79. Erickson K, Patterson RE, Flatt SW, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol. 2011 Jan 1;29(1):54-60.
  80. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer. 2006 Jul 1;119(1):236-8.
  81. J. Goodwin M, Ennis KI, Pritchard, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42–51.
  82. Railo J, Smitten KV, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer. 1994 Part A; 30(3):307–11.
  83. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Research. 1997;57(15):3079–83.
  84. Hickish T, Astras G, Thomas P, et al. Glucose intolerance during adjuvant chemotherapy for breast cancer. J Nat Cancer Inst. 2009;101(7):537.
  85. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000 Dec;49(12):2063-9.
  86. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999;58 Suppl 1:31-9; discussion 75-82.
  87. Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. J Agric Food Chem. 2010 Apr 14;58(7):4141-4.
  88. Nagendran MV. Effect of green coffee bean extract (GCE), high in chlorogenic acids, on glucose metabolism. Poster presentation number: 45-LB-P. Obesity 2011, the 29th Annual Scientific Meeting of the Obesity Society. Orlando, Florida. October 1-5, 2011.
  89. Available at: Mechanism_of_Diease_Atherosclerosis_and_CAD.pdf. Accessed February 4, 2013.
  90. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other mark-ers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 342:836-43.
  91. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res. 2002 Jan;52(1):1-23.
  92. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, and Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–21.
  93. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci. 2008;13:5094-107.
  94. Sgambato A, Cittadini A. Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):263-8.
  95. Schmidt R, Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study, Ann Neurol. 2002 Aug;52(2):168-74.
  96. Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem. 2009 Mar;108(6):1343-59.
  97. Schram MT, Euser SM, de Craen AJ, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007 May;55(5):708-16.
  98. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011 Jul-Aug;48(4):155-70.
  99. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011 Jun 3;13(3):R55.
  100. Imai N, Kinoshita A, Onoda H, et al. Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clin Transl Oncol. 2012 Dec 21. [Epub ahead of print]
  101. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009 Jul 20;27(21):3437-44.
  102. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009 May 1;27(13):2217-24.
  103. Heikkilä K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009 Feb;20(1):15-26.
  104. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006 Nov 20;24(33):5216-22.
  105. Il’yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8.
  106. Shen L, Li ZM, Lu S. Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):442-6.
  107. Alifano M, Falcoz PE, Seegers V, et al. Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. Thorac Cardiovasc Surg. 2011 Nov;142(5):1161-7.
  108. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010 Jun 1;28(16):2719-26.
  109. Alfano CM, Imayama I, Neuhouser ML, et al. Fatigue, inflammation, and ω-3 and ω-6 fatty acid intake among breast cancer survivors. J Clin Oncol. 2012 Apr 20;30(12):1280-7.
  110. Ko YJ, Kwon YM, Kim KH, et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2076-86.
  111. Lee S, Choe JW, Kim HK, Sung J. High-sensitivity C-reactive protein and cancer. J Epidemiol. 2011;21(3):161-8.
  112. Woo Y, Hyung WJ, Obama K, et al. Elevated high-sensitivity C-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence. J Surg Oncol. 2012 Mar 15;105(4):405-9.
  113. Ridker PM. Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation. 2003 Sep 23;108(12):e81-5.